Central Nervous System Lymphoma Clinical Trials

50 clinical trials for Central Nervous System Lymphoma across international registries, including 14 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Loncastuximab Tesirine and Rituximab Following Stereotactic Radiosurgery in Patients With Central Nervous System Lymphomas (SOLAR) — RECRUITING · PHASE1
• Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU — RECRUITING
• A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL) — RECRUITING · PHASE1
• DALY II USA/ MB-CART2019.1 for DLBCL — RECRUITING · PHASE2
• Intracerebroventricular Administration of CD19-CAR T Cells (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/Mem T-lymphocytes) for the Treatment of Central Nervous System Lymphoma — RECRUITING · PHASE1
• Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies — RECRUITING
• CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies — RECRUITING · PHASE1
• Thiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma — RECRUITING · PHASE2
• Long-term Follow-up Study of Patients Receiving CAR-T Cells — RECRUITING
• Selinexor in Combination With MTX+Ritu to Treat R/R CNSL — RECRUITING · PHASE1
• Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL). — RECRUITING · PHASE1
• Orelabrutinib Combined With Pemetrexed For Relapsed/Refractory Central Nervous System Lymphoma — RECRUITING · PHASE2
• A PHASE 2 STUDY OF IBRUTINIB COMBINATION THERAPY IN TRANSPLANT INELIGIBLE INDIVIDUALS WITH NEWLY DIAGNOSED PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA — RECRUITING · PHASE2
• Lenalidomide Maintenance Treatment in Patients With Primary Central Nervous System Lymphoma — RECRUITING · PHASE2
• MIDNOR-STROKE- a Long Term Follow-up Study of Patients With First Ever Ischemic Stroke in Central Norway — ACTIVE_NOT_RECRUITING
• Acalabrutinib in CNSL — ACTIVE_NOT_RECRUITING · PHASE1
• A Pilot Study of Acalabrutinib in Relapsed/Refractory Primary and Secondary CNS Lymphomas — ACTIVE_NOT_RECRUITING · PHASE2
• Human CD19-CD22 Targeted T Cells Injection for Refractory/Relapsed Central Nervous System Leukemia/Lymphoma Patients — ACTIVE_NOT_RECRUITING · PHASE1
• Golcadomide With Pemetrexed, Rituximab, and Dexamethasone for Relapsed and Refractory CNS Lymphomas — NOT_YET_RECRUITING · PHASE1
• A PHASE 3, MULTI-REGIONAL, OPEN-LABEL, RANDOMIZED STUDY OF TIRABRUTINIB VS RITUXIMAB AND TEMOZOLOMIDE IN PARTICIPANTS WITH RELAPSED/REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA — NOT_YET_RECRUITING · PHASE3
• Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS) — ACTIVE_NOT_RECRUITING · PHASE2
• LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma — ACTIVE_NOT_RECRUITING · PHASE1
• Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma — COMPLETED · PHASE2
• Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom — ACTIVE_NOT_RECRUITING · PHASE2
• Zillion: Zanubrutinib Combined With Chemotherapy for Newly Diagnosed CNS Lymphoma — NOT_YET_RECRUITING · PHASE2
• Pharmacogenomics Effects on High-Dose Methotrexate Clearance in Patients With Diffuse Large B-Cell Lymphoma — COMPLETED
• High-dose Chemotherapy with Thiotepa, Busulfan, and Cyclophosphamide Followed by Autologous Stem Cell Transplantation in Central Nervous System Lymphoma — TERMINATED · PHASE2
• Secondary Central Nervous System Lymphoma Registry - Charité — OTHER
• Decitabine and Anti-PD-1 in R/R DLBCL — OTHER · PHASE2
• Randomized Phase II Trial On Primary Chemotherapy With High-Dose Methotrexate And High-Dose Cytarabine With Or Without Thiotepa, And With Or Without Rituximab, Followed By Brain Irradiation Vs. High-Dose Chemotherapy Supported By Autologous Stem Cells Transplantation For Immunocompetent Patients With Newly Diagnosed Primary CNS Lymphoma — OTHER
• Using a Novel Functional MRI Technique to Evaluate for Neurotoxicity — COMPLETED
• Nordic Study in Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma — COMPLETED · PHASE2
• Ferumoxytol in Improving MR Imaging in Patients With High-Grade Brain Tumors or Cerebral Metastases — COMPLETED · NA
• Bruton's Tyrosine Kinase Inhibitor Ibrutinib as Maintenance Treatment in Elderly Patients With Primary CNS Lymphoma — OTHER · PHASE2
• Akt/ERK Inhibitor ONC201 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma — TERMINATED · PHASE1
• A PHASE 1B/2, OPEN-LABEL DOSE ESCALATION WITH EXPANSION STUDY OF GB5121 IN ADULT SUBJECTS WITH RELAPSED/REFRACTORY PRIMARY OR SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA, WITH A PHASE 2 OPEN-LABEL SINGLE DOSE LEVEL STUDY OF GB5121 IN ADULT SUBJECTS WITH RELAPSED/REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA — COMPLETED · PHASE2
• Intermediate Dose of IV MTX as CNS Prophylaxis for High Risk DLBCL — OTHER · PHASE3
• Methotrexate, Mannitol, Rituximab, and Carboplatin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma — OTHER · PHASE1
• Rituximab,Zanubrutinib in Combination With Lenalidomide, Followed by Zanubrutinib or Lenalidomide Maintenance in Patients With Primary or Secondary CNS Lymphoma — OTHER · PHASE2
• A Phase II Trail of Chidamide ,Rituximab and Methotrexate in Lymphoma Patients — OTHER · PHASE2
• Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma — COMPLETED · NA
• Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma or Newly Diagnosed or Relapsed or Refractory Intraocular Lymphoma — COMPLETED · PHASE1
• Molecular Prognosis of Lymphomas of the Central Nervous System (ALYCE-molecular) — OTHER
• Long-term Outcome of AIDS-related Primary Central Nervous System Lymphoma Treated With High Dose Methotrexate and Combined Antiretroviral Therapy — COMPLETED
• A PHASE 2, OPEN-LABEL, SINGLE-ARM, TWO-COHORT STUDY OF NIVOLUMAB IN RELAPSED/REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL) OR RELAPSED/REFRACTORY PRIMARY TESTICULAR LYMPHOMA (PTL) — COMPLETED · PHASE2
• Study of Tissue Samples From Patients With Glioma or Other Brain Tumors — COMPLETED
• Treatment of Recurrent Primary or Secondary Central Nervous System (CNS) Lymphoma With ALIMTA (Pemetrexed) — COMPLETED · PHASE1
• A Safety Study of Rituximab Plus MTX Injected Into the Cerebrospinal Fluid in the Treatment of Brain Lymphoma — COMPLETED · PHASE1
• Cognitive Functioning and Quality of Life in CNS Lymphoma — COMPLETED
• Whole Brain Irradiation in Primary Central Nervous System (CNS) Lymphoma (PCNSL) — COMPLETED · PHASE4

Refine this search